ÂÜÀòÂÒÂ×

Ton Berkien serves as Chief Business Officer at Cantargia AB since October 2024 and has held the position of Chairman Of The Board Of Directors at Gedea Biotech AB since June 2021. Additionally, Ton Berkien is a Board Member at AdjuTec Pharma AS and was previously Chief Business Officer at Ultimovacs until October 2024, and Director of Business Development at Amgen from August 2019 to December 2020. A former Chief Business Officer at Nuevolution from January 2014 to December 2020, Ton Berkien also served as Director of Corporate Development/Mergers & Acquisitions at Takeda from May 2007 to December 2013, managing significant responsibilities in M&A and strategy. Prior experience includes a Director role in Competitive Intelligence at Ferring Pharmaceuticals and Senior Manager of Business Intelligence Corporate Finance at PricewaterhouseCoopers. Early in the career, Ton Berkien was a Business Intelligence Manager at Rijnconsult. Educational qualifications include an LSid from Harvard Business School/IMD/PwC, a degree from the Scandinavian International Management Institute, and a diploma from Saxion University of Applied Sciences.